370 related articles for article (PubMed ID: 32366290)
1. Mesenchymal stem cells as a potential therapy for COVID-19.
Liu S; Peng D; Qiu H; Yang K; Fu Z; Zou L
Stem Cell Res Ther; 2020 May; 11(1):169. PubMed ID: 32366290
[TBL] [Abstract][Full Text] [Related]
2. Overview of Stem Cell Therapy for Acute Respiratory Distress Syndrome with Focus on COVID 19.
Kaye RJ
Pain Physician; 2020 Aug; 23(4S):S421-S432. PubMed ID: 32942797
[TBL] [Abstract][Full Text] [Related]
3. MSCs transplantation may be a potential therapeutic strategy for COVID-19 treatment.
Wang XY
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4537-4538. PubMed ID: 32373992
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal stem cells: current clinical progress in ARDS and COVID-19.
Xiao K; Hou F; Huang X; Li B; Qian ZR; Xie L
Stem Cell Res Ther; 2020 Jul; 11(1):305. PubMed ID: 32698898
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulation and Regeneration Properties of Dental Pulp Stem Cells: A Potential Therapy to Treat Coronavirus Disease 2019.
Zayed M; Iohara K
Cell Transplant; 2020; 29():963689720952089. PubMed ID: 32830527
[TBL] [Abstract][Full Text] [Related]
6. Rationale for the Use of Radiation-Activated Mesenchymal Stromal/Stem Cells in Acute Respiratory Distress Syndrome.
Tovar I; Guerrero R; López-Peñalver JJ; Expósito J; Ruiz de Almodóvar JM
Cells; 2020 Sep; 9(9):. PubMed ID: 32887260
[TBL] [Abstract][Full Text] [Related]
7. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics.
Qin H; Zhao A
Protein Cell; 2020 Oct; 11(10):707-722. PubMed ID: 32519302
[TBL] [Abstract][Full Text] [Related]
8. Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients.
Rogers CJ; Harman RJ; Bunnell BA; Schreiber MA; Xiang C; Wang FS; Santidrian AF; Minev BR
J Transl Med; 2020 May; 18(1):203. PubMed ID: 32423449
[TBL] [Abstract][Full Text] [Related]
9. Cell-based therapies for coronavirus disease 2019: proper clinical investigations are essential.
Khoury M; Rocco PRM; Phinney DG; Krampera M; Martin I; Viswanathan S; Nolta JA; LeBlanc K; Galipeau J; Weiss DJ
Cytotherapy; 2020 Nov; 22(11):602-605. PubMed ID: 32933835
[TBL] [Abstract][Full Text] [Related]
10. Mesenchymal Stem Cell Therapy Can Transcend Perianal Crohn's Disease: How Colorectal Surgeons Can Help in the Coronavirus Disease 2019 Crisis.
Lightner AL; García-Olmo D
Dis Colon Rectum; 2020 Jul; 63(7):874-878. PubMed ID: 32251143
[No Abstract] [Full Text] [Related]
11. Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatment.
Jayaramayya K; Mahalaxmi I; Subramaniam MD; Raj N; Dayem AA; Lim KM; Kim SJ; An JY; Lee Y; Choi Y; Raj A; Cho SG; Vellingiri B
BMB Rep; 2020 Aug; 53(8):400-412. PubMed ID: 32731913
[TBL] [Abstract][Full Text] [Related]
12. Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19.
Khoury M; Cuenca J; Cruz FF; Figueroa FE; Rocco PRM; Weiss DJ
Eur Respir J; 2020 Jun; 55(6):. PubMed ID: 32265310
[TBL] [Abstract][Full Text] [Related]
13. Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients.
Al-Khawaga S; Abdelalim EM
Stem Cell Res Ther; 2020 Oct; 11(1):437. PubMed ID: 33059757
[TBL] [Abstract][Full Text] [Related]
14. The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019.
Canham MA; Campbell JDM; Mountford JC
J Transl Med; 2020 Sep; 18(1):359. PubMed ID: 32958009
[TBL] [Abstract][Full Text] [Related]
15. [Therapy of coronavirus disease 2019 induced acute respiratory distress syndrome is different from traditional acute respiratory distress syndrome].
Pan C; Xie JF; Qiu HB; Yang Y
Zhonghua Shao Shang Za Zhi; 2020 May; 36(5):330-333. PubMed ID: 32456368
[TBL] [Abstract][Full Text] [Related]
16. Mesenchymal stem cells and exosome therapy for COVID-19: current status and future perspective.
Gupta A; Kashte S; Gupta M; Rodriguez HC; Gautam SS; Kadam S
Hum Cell; 2020 Oct; 33(4):907-918. PubMed ID: 32780299
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
[TBL] [Abstract][Full Text] [Related]
18. Inflammation, Thrombosis, and Destruction: The Three-Headed Cerberus of Trauma- and SARS-CoV-2-Induced ARDS.
Lupu L; Palmer A; Huber-Lang M
Front Immunol; 2020; 11():584514. PubMed ID: 33101314
[TBL] [Abstract][Full Text] [Related]
19. Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome.
Qu W; Wang Z; Hare JM; Bu G; Mallea JM; Pascual JM; Caplan AI; Kurtzberg J; Zubair AC; Kubrova E; Engelberg-Cook E; Nayfeh T; Shah VP; Hill JC; Wolf ME; Prokop LJ; Murad MH; Sanfilippo FP
Stem Cells Transl Med; 2020 Sep; 9(9):1007-1022. PubMed ID: 32472653
[TBL] [Abstract][Full Text] [Related]
20. Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies.
Zumla A; Wang FS; Ippolito G; Petrosillo N; Agrati C; Azhar EI; Chang C; El-Kafrawy SA; Osman M; Zitvogel L; Galle PR; Locatelli F; Gorman E; Cordon-Cardo C; O'Kane C; McAuley D; Maeurer M
Int J Infect Dis; 2020 Jul; 96():431-439. PubMed ID: 32425638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
